within Pharmacolibrary.Drugs.ATC.A;

model A06AA51
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.03,
    Cl             = 4.9999999999999996e-06,
    adminDuration  = 600,
    adminMass      = 15000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A06AA51</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Liquid paraffin, in combination with other agents, is used primarily as a laxative for the treatment of constipation. It forms a smooth, slippery film that coats the bowel and the stool, preventing water from leaving the stool, thus easing its passage. Its use has declined due to concerns about aspiration and lipid pneumonia, and it is less commonly recommended today.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic studies for liquid paraffin combinations with ATC code A06AA51 in humans are available in published literature. No model-based PK parameters reported for dose, absorption, or elimination. The following values are estimated based on physicochemical characteristics and typical oral administration in adults.</p><h4>References</h4><ol><li><p>Holub, D, et al., &amp; Dzubak, P (2019). Mass Spectrometry Amyloid Typing Is Reproducible across Multiple Organ Sites. <i>BioMed research international</i> 2019 3689091–None. DOI:<a href=\"https://doi.org/10.1155/2019/3689091\">10.1155/2019/3689091</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30834260/\">https://pubmed.ncbi.nlm.nih.gov/30834260</a></p></li><li><p>Ali, J, et al., &amp; Ali, M (2006). Formulation and development of gastroretentive drug delivery system for ofloxacin. <i>Methods and findings in experimental and clinical pharmacology</i> 28(7) 433–439. DOI:<a href=\"https://doi.org/10.1358/mf.2006.28.7.1003574\">10.1358/mf.2006.28.7.1003574</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17003848/\">https://pubmed.ncbi.nlm.nih.gov/17003848</a></p></li><li><p>Trapani, A, et al., &amp; Liso, G (2007). Eudragit RS 100 microparticles containing 2-hydroxypropyl-beta-cyclodextrin and glutathione: physicochemical characterization, drug release and transport studies. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 30(1) 64–74. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2006.10.003\">10.1016/j.ejps.2006.10.003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17118631/\">https://pubmed.ncbi.nlm.nih.gov/17118631</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A06AA51;
